Adamax
Cognitive & MoodAlso known as: Adamax Peptide, Semax-Adamantane, Ac-MEHFPGPAG-NH2
Mechanism
Adamax is an advanced version of Semax, one of Russia's most well-known brain-boosting peptides. It has been modified with an adamantane group — the same chemical structure found in certain Alzheimer's drugs — which helps it cross the blood-brain barrier more effectively and last longer in the body. Users report stronger and more sustained improvements in focus, memory, and mood compared to regular Semax. It is considered the most potent Semax derivative available.
Technical detail
Adamax is a synthetic nonapeptide analog of Semax (MEHFPGP) modified with N-terminal acetylation and incorporation of an adamantyl moiety, enhancing lipophilicity and blood-brain barrier penetration. The adamantane cage structure increases metabolic stability against peptidases while improving CNS bioavailability. Proposed mechanism includes upregulation of BDNF expression and enhanced TrkB receptor sensitivity in hippocampal neurons, modulation of monoaminergic neurotransmission (dopamine, norepinephrine, serotonin), and stabilization of microtubules via ADNP-derived pathways. Exhibits antioxidant and anti-inflammatory neuroprotective properties. Parent compound Semax is derived from ACTH(4-10) fragment with a Pro-Gly-Pro C-terminal extension for protease resistance.
Effects
NEUROLOGICAL: Primary target organ. Enhanced version of Semax with superior blood-brain barrier penetration due to adamantane lipophilicity. Upregulates brain-derived neurotrophic factor (BDNF) expression in hippocampus — BDNF is the key neurotrophin for synaptic plasticity, learning, and memory consolidation (based on parent compound Semax data, multiple animal studies). Enhances TrkB receptor sensitivity (the BDNF receptor), amplifying neurotrophic signaling. Modulates monoaminergic neurotransmission: increases dopamine and norepinephrine turnover in prefrontal cortex (focus, motivation), and serotonin in raphe nuclei (mood regulation). Parent compound Semax increases NGF expression in hippocampus and basal forebrain (animal). Reported to be 2-3x more potent than standard Semax analogs for endurance and cognitive enhancement (community reports, not peer-reviewed). Neuroprotective: reduces oxidative stress markers in CNS tissue, stabilizes microtubules via ADNP-derived mechanisms (proposed, based on structural analogy). Anti-inflammatory in CNS: reduces microglial activation markers (animal, parent compound data). CARDIOVASCULAR: Semax-family peptides modulate vascular tone via endothelin and nitric oxide pathways (animal). Parent compound Semax has been studied for stroke recovery in Russian clinical settings — improved neurological outcomes when administered within 6 hours of ischemic stroke (Russian clinical data, Tier 3). IMMUNE: Semax modulates immune function — influences T-cell and macrophage activity, affects expression of immune-related genes in brain and peripheral tissues (animal). Anti-inflammatory cytokine profile shift noted with parent compound. ENDOCRINE: Derived from ACTH(4-10) fragment but does not stimulate adrenal cortisol production. No significant HPA axis activation at therapeutic doses (parent compound data). METABOLIC: The adamantane moiety (also found in memantine, amantadine) is associated with NMDA receptor modulation — potential for mild glutamate regulation at higher doses (theoretical, based on structural similarity). Tier 3: Biohacking community consistently rates Adamax as the strongest Semax derivative for sustained focus and anxiolysis. Reports suggest 4-8 hour duration of cognitive effects. Intranasal administration is preferred route for CNS delivery.
Practitioner Guide
DOSING TIPS: Typically administered intranasally for optimal CNS delivery. Common protocol: 100-300 mcg per nostril, 1-2 times daily. Start at the low end (100 mcg per nostril once daily) and titrate based on response. Some users prefer sublingual administration as an alternative. Injectable (subcutaneous) is less common but used by some practitioners at 200-500 mcg/day. RECONSTITUTION: For injectable use — reconstitute lyophilized powder with bacteriostatic water. For nasal spray — typically purchased as pre-made nasal spray solution (200 mcg/spray is common). If compounding from powder, use sterile saline as vehicle for nasal application. TIMING: Morning administration preferred for cognitive enhancement — effects can last 4-8 hours and may interfere with sleep if taken late. Some users add a second dose at midday for sustained effects. Take on empty stomach (nasal route bypasses GI anyway). SUPPLEMENT SYNERGIES: Stacks well with other nootropics in the racetam family (piracetam, aniracetam) — Semax-family peptides and racetams have complementary mechanisms (BDNF upregulation + cholinergic modulation). Combine with choline source (Alpha-GPC, CDP-choline) for acetylcholine support. Lion's Mane mushroom (NGF upregulation) is a natural complement. Omega-3 fatty acids support the neuroplasticity that BDNF promotes. Magnesium L-threonate for additional NMDA modulation. CYCLING: Recommended — 4-6 weeks on, 2-4 weeks off. Tolerance has been reported with continuous use (parent compound Semax). Some practitioners use 5 days on, 2 days off schedule. The adamantane modification may extend effective duration before tolerance develops, but this is anecdotal. STACKING: Nootropic stack: Adamax + N-Acetyl Selank Amidate (anxiolysis + focus). Cognitive recovery stack: Adamax + Cerebrolysin + Dihexa. Combine with Pinealon for sleep/cognitive dual benefit. Do NOT stack with other strong dopaminergic compounds (risk of overstimulation). CONTRAINDICATION NUANCES: Patients with bipolar disorder should use with extreme caution — dopaminergic enhancement may trigger manic episodes. Avoid with MAOIs. May potentiate stimulant medications (Adderall, modafinil) — reduce stimulant dose if combining. Patients with anxiety may paradoxically experience increased anxiety at higher doses despite parent compound's anxiolytic properties — start low. STORAGE: Lyophilized powder — room temperature, protect from light and moisture. Nasal spray solutions — refrigerate after opening, use within 4-6 weeks. PATIENT EDUCATION: Explain that this is the strongest available Semax derivative. Effects are noticeable within 15-30 minutes intranasally. Cognitive benefits are real but subtle — this is not a stimulant. The adamantane group comes from the same chemical family as memantine (Alzheimer's drug) and amantadine (Parkinson's drug), giving it additional neuroprotective properties. Best suited for knowledge workers, students, or anyone seeking sustained mental clarity without stimulant side effects.
Research Summary
TIER 1 (Gold Standard): No direct clinical trials exist for Adamax specifically. Parent compound Semax has Russian pharmaceutical registration and extensive clinical use data. BDNF upregulation by Semax-family peptides is well-documented (multiple animal studies, peer-reviewed). TIER 2 (Strong): Semax clinical data from Russia — approved as a nootropic and neuroprotective agent. Semax for ischemic stroke — Russian clinical studies showing improved neurological outcomes (cited in Russian pharmacological literature). Dolotov et al. — Semax increases BDNF and NGF in rat hippocampus (PMID: 16394986). Eremin et al. — Semax modulates expression of genes involved in immune response and neuroplasticity. Examine.com and DrugBank entries for Semax as parent compound. TIER 3 (Moderate): Adamantane pharmacology well-characterized in memantine and amantadine literature — NMDA receptor modulation, neuroprotection. Practitioner protocols for Semax derivatives including Adamax from nootropic-focused clinics. Community reports on self-experimentation forums (Longecity, Reddit r/nootropics) consistently report Adamax as strongest Semax variant. International data: Russian clinical use of Semax family spans 20+ years. KEY FINDINGS: (1) The adamantane modification is a rational pharmacological enhancement with precedent. (2) Parent compound Semax has strong evidence for BDNF upregulation and neuroprotection. (3) No independent Western validation of Adamax specifically. (4) Community consensus on potency exceeding other Semax derivatives is consistent. GAPS: No published studies on Adamax itself. Pharmacokinetic data unknown. Optimal dosing undefined. Long-term safety unstudied. ACTIVE TRIALS: None registered for Adamax on ClinicalTrials.gov.